ArticleAmerican journal of ophthalmology case reports2024
Progressive anterior segment involvement of an infant with corneoscleral juvenile xanthogranuloma refractory to topical steroids.
Article in American journal of ophthalmology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a case of corneoscleral juvenile xanthogranuloma (JXG) with progressive anterior segment involvement refractory to topical steroids. Observations: A 4-month-old male was referred for a new-onset subconjunctival lesion in the right eye. He was found to have a thickened, yellow corneoscleral lesion and hyphema, presumed to be ocular JXG. He was started on topical steroids as empiric treatment, with initial improvement for the first 3 months. Despite remaining on topical steroids, the lesion persisted and was biopsied at age 8 months. Conjunctival, scleral, and aqueous biopsies ruled out uveitic and malignant etiologies and were consistent with JXG with CD68-positive histiocytes, CD3-positive T cells, and CD20-positive B cells. Over the next few months, axial length increased out of proportion to normal growth, and intraocular pressure was elevated despite multiple pressure-lowering drops. At age 11 months, the patient acutely developed a flat anterior chamber with complete keratolenticular and iridocorneal adhesions secondary to a pupillary membrane. The patient improved after undergoing placement of an Ahmed drainage implant, synechiolysis, pars plana lensectomy and vitrectomy, subconjunctival and intravitreal injection of bevacizumab, and intravitreal methotrexate. Conclusions and importance: This is a rare presentation of ocular JXG presenting with diffuse infiltration of the sclera, cornea, and iris. Given the involvement of multiple ocular structures, progression despite initial response to topical steroids, and increased intraocular pressure, aggressive management was required. Lesions should be closely monitored for progression and may benefit from surgical intervention and treatment with intraocular bevacizumab and/or methotrexate if topical steroids are insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.